Replies to post #2253 on Dendreon Corp fka DNDNQ

[steveporsche]

Yes, I am very well aware of the problems with Allos' subgroups analyses. My desire was not to bring these up here again. According to Allos, the cox was significant for surival for the entire ITT as well. My desire was to bring up a quote I found by an FDA reviewer said cox should not be considered a substitute for a failed log rank. Wall's response on IV that this quote should be probably best applied to a pivotal trial (like ALTH's) and not a supportive trial like 9902a makes sense to me. Hopefully, it will to the FDA as well.